BR112022018462A2 - Formulações líquidas de análogos de glucagon - Google Patents
Formulações líquidas de análogos de glucagonInfo
- Publication number
- BR112022018462A2 BR112022018462A2 BR112022018462A BR112022018462A BR112022018462A2 BR 112022018462 A2 BR112022018462 A2 BR 112022018462A2 BR 112022018462 A BR112022018462 A BR 112022018462A BR 112022018462 A BR112022018462 A BR 112022018462A BR 112022018462 A2 BR112022018462 A2 BR 112022018462A2
- Authority
- BR
- Brazil
- Prior art keywords
- liquid formulations
- formulations
- glucagon analogs
- glucagon
- dose
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Child & Adolescent Psychology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20163408 | 2020-03-16 | ||
| PCT/EP2021/056651 WO2021185821A1 (en) | 2020-03-16 | 2021-03-16 | Liquid formulations of glucagon analogues |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022018462A2 true BR112022018462A2 (pt) | 2022-11-01 |
Family
ID=70008261
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022018462A BR112022018462A2 (pt) | 2020-03-16 | 2021-03-16 | Formulações líquidas de análogos de glucagon |
Country Status (23)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL312600B2 (en) | 2022-05-30 | 2025-12-01 | Zealand Pharma As | Liquid formulations of amylin analogs |
| WO2025056677A1 (en) | 2023-09-15 | 2025-03-20 | Zealand Pharma A/S | Dasiglucagon for use in the treatment of congenital hyperinsulinism |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0700523D0 (en) | 2007-01-11 | 2007-02-21 | Insense Ltd | The Stabilisation Of Proteins |
| WO2011117417A1 (en) | 2010-03-26 | 2011-09-29 | Novo Nordisk A/S | Novel glucagon analogues |
| NZ704043A (en) * | 2012-07-23 | 2017-07-28 | Zealand Pharma As | Glucagon analogues |
| US9018162B2 (en) | 2013-02-06 | 2015-04-28 | Xeris Pharmaceuticals, Inc. | Methods for rapidly treating severe hypoglycemia |
| UA121874C2 (uk) | 2015-02-17 | 2020-08-10 | Елі Ліллі Енд Компані | Порошкова назальна композиція для лікування гіпоглікемії |
| WO2017053822A1 (en) | 2015-09-23 | 2017-03-30 | Behavioral Recognition Systems, Inc. | Detected object tracker for a video analytics system |
| GB201710822D0 (en) * | 2017-07-05 | 2017-08-16 | Zealand Pharma As | Methods and medical uses relating to the treatment of hypoglycaemia |
| WO2019110838A1 (fr) | 2017-12-07 | 2019-06-13 | Adocia | Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide |
-
2021
- 2021-03-16 BR BR112022018462A patent/BR112022018462A2/pt unknown
- 2021-03-16 PH PH1/2022/552457A patent/PH12022552457A1/en unknown
- 2021-03-16 PE PE2022001968A patent/PE20230258A1/es unknown
- 2021-03-16 EP EP21712156.5A patent/EP4121003B1/en active Active
- 2021-03-16 HR HRP20251267TT patent/HRP20251267T1/hr unknown
- 2021-03-16 KR KR1020227031361A patent/KR102956482B1/ko active Active
- 2021-03-16 JP JP2022555741A patent/JP7834025B2/ja active Active
- 2021-03-16 HU HUE21712156A patent/HUE073401T2/hu unknown
- 2021-03-16 UA UAA202203796A patent/UA129439C2/uk unknown
- 2021-03-16 PL PL21712156.5T patent/PL4121003T3/pl unknown
- 2021-03-16 ES ES21712156T patent/ES3041327T3/es active Active
- 2021-03-16 US US17/203,126 patent/US20210283053A1/en not_active Abandoned
- 2021-03-16 WO PCT/EP2021/056651 patent/WO2021185821A1/en not_active Ceased
- 2021-03-16 MX MX2022011227A patent/MX2022011227A/es unknown
- 2021-03-16 CN CN202180021174.4A patent/CN115279341B/zh active Active
- 2021-03-16 IL IL295977A patent/IL295977A/en unknown
- 2021-03-16 RS RS20250960A patent/RS67245B1/sr unknown
- 2021-03-16 CA CA3171184A patent/CA3171184A1/en active Pending
- 2021-03-16 AR ARP210100659A patent/AR121581A1/es unknown
- 2021-03-16 TW TW110109431A patent/TW202200190A/zh unknown
- 2021-03-16 AU AU2021236878A patent/AU2021236878B2/en active Active
-
2022
- 2022-09-09 CL CL2022002472A patent/CL2022002472A1/es unknown
- 2022-10-11 CO CONC2022/0014452A patent/CO2022014452A2/es unknown
-
2024
- 2024-12-20 US US18/989,423 patent/US20250195424A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2022011227A (es) | 2022-10-07 |
| CN115279341A (zh) | 2022-11-01 |
| EP4121003C0 (en) | 2025-08-06 |
| AU2021236878A1 (en) | 2022-09-29 |
| JP7834025B2 (ja) | 2026-03-23 |
| US20210283053A1 (en) | 2021-09-16 |
| HUE073401T2 (hu) | 2026-01-28 |
| HRP20251267T1 (hr) | 2025-12-05 |
| PE20230258A1 (es) | 2023-02-07 |
| KR102956482B1 (ko) | 2026-04-23 |
| EP4121003A1 (en) | 2023-01-25 |
| TW202200190A (zh) | 2022-01-01 |
| AR121581A1 (es) | 2022-06-15 |
| WO2021185821A1 (en) | 2021-09-23 |
| CL2022002472A1 (es) | 2023-02-17 |
| PL4121003T3 (pl) | 2026-02-23 |
| JP2023518052A (ja) | 2023-04-27 |
| US20250195424A1 (en) | 2025-06-19 |
| KR20220154110A (ko) | 2022-11-21 |
| CA3171184A1 (en) | 2021-09-23 |
| ES3041327T3 (en) | 2025-11-11 |
| RS67245B1 (sr) | 2025-10-31 |
| PH12022552457A1 (en) | 2023-12-11 |
| AU2021236878B2 (en) | 2025-09-11 |
| CN115279341B (zh) | 2026-03-31 |
| NZ791927A (en) | 2025-09-26 |
| EP4121003B1 (en) | 2025-08-06 |
| UA129439C2 (uk) | 2025-04-23 |
| CO2022014452A2 (es) | 2022-10-21 |
| IL295977A (en) | 2022-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20242299A1 (es) | Composiciones agonistas de gip/glp1 | |
| MX2024005304A (es) | Derivado del acido fenilpropionico sustituido y uso del mismo. | |
| MX2017011280A (es) | Terapia neuro-afectiva regional topica con cannabinoides. | |
| BR112015018252A2 (pt) | composição farmacêutica aquosa de dose fixa estável para administração nasal para um ser humano, composição de suspensão aquosa farmacêutica de dose fixa estável para administração nasal para um ser humano, suspensão estável adequada para administração nasal a um ser humano, método para tratar rinite em um ser humano necessitando do mesmo, uso da composição farmacêutica para administração nasal, método para liberar uma composição farmacêutica e kit | |
| AR095114A1 (es) | Formulaciones farmacéuticas estabilizadas de análogos de insulina y/o derivados de insulina | |
| CL2025001801A1 (es) | Uso de aflibercept para tratar o prevenir retinopatía diabética y/o el edema macular diabético. | |
| AR070026A1 (es) | Conjunto de elementos para la dosificacion de 1-amino-alquilciclohexanos, tal como neramexano, y tratamiento de diversas enfermedades incluyendo el tinnitus | |
| BR112021018506A2 (pt) | Terapia de combinação para tratamento do câncer | |
| CL2021001636A1 (es) | Composición farmacéutica para el tratamiento de la hipertensión arterial pulmonar | |
| MX2009013183A (es) | Uso de la proteina de fusion taci-ig, tal como atacicept, para la elaboracion de un medicamento para tratar lupus eritematoso. | |
| MX2021012708A (es) | Formulaciones novedosas que comprenden melflufen. | |
| CL2021000290A1 (es) | Un método de obtención de la forma de dosis líquida del medicamento edaravone, que es estable durante el almacenamiento, transporte y de uso conveniente | |
| CL2022002472A1 (es) | Formulaciones líquidas de análogos de glucagón | |
| CL2018000363A1 (es) | Derivados del ácido 5-(n-bencil-tetrahidroisoquinolin-6-il)-piridin-3-il acético como inhibidores de la replicación del virus de la inmunodeficiencia humana. | |
| BR112017001160A2 (pt) | [1,2,4]triazol[4,3-b]piridazinas para uso no tratamento de doenças proliferativas | |
| BR112023020538A2 (pt) | Derivados heterocíclicos, composições farmacêuticas e seus usos no tratamento ou na melhoria de câncer | |
| CL2021002107A1 (es) | Triamtereno o nolatrexed para uso en el tratamiento de fenilcetonuria. | |
| CL2020001738A1 (es) | Preparación de absorción percutánea para el tratamiento de la demencia que contiene donepezilo. | |
| MX2020010747A (es) | Formulaciones topicas que comprenden estroncio y metilsulfonilmetano (msm) y metodos de tratamiento. | |
| BR112022021546A2 (pt) | Composições e métodos para entregar agentes farmaceuticamente ativos | |
| MX2021008329A (es) | Farmaco profilactico o terapeutico para enfermedades neurodegenerativas. | |
| CO2020000292A2 (es) | Preparación medicinal combinada para tratar infecciones virales | |
| BR112016015175A2 (pt) | Formulação farmacêutica, método para a fabricação de uma formulação farmacêutica compreendendo sildenafila e clomipramina e comprimido | |
| BR112018072183A2 (pt) | composição farmacêutica, e, método para prevenir uma doença de pele | |
| AR110319A1 (es) | Composición para el tratamiento de la osteoartritis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |